These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 28368960)

  • 1. Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation.
    Yu G; Moudgil T; Cui Z; Mou Y; Wang L; Fox BA; Hu HM
    J Immunother; 2017 Jun; 40(5):155-163. PubMed ID: 28368960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ubiquitinated proteins enriched from tumor cells by a ubiquitin binding protein Vx3(A7) as a potent cancer vaccine.
    Aldarouish M; Wang H; Zhou M; Hu HM; Wang LX
    J Exp Clin Cancer Res; 2015 Apr; 34(1):34. PubMed ID: 25886865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-presentation of viral antigens in dribbles leads to efficient activation of virus-specific human memory T cells.
    Ye W; Xing Y; Paustian C; van de Ven R; Moudgil T; Hilton TL; Fox BA; Urba WJ; Zhao W; Hu HM
    J Transl Med; 2014 Apr; 12():100. PubMed ID: 24735498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells.
    Mahdian R; Kokhaei P; Najar HM; Derkow K; Choudhury A; Mellstedt H
    Med Oncol; 2006; 23(2):273-82. PubMed ID: 16720928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
    J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.
    Aarntzen EH; Bol K; Schreibelt G; Jacobs JF; Lesterhuis WJ; Van Rossum MM; Adema GJ; Figdor CG; Punt CJ; De Vries IJ
    Cancer Res; 2012 Dec; 72(23):6102-10. PubMed ID: 23010076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients.
    Castelli C; Mazzocchi A; Rini F; Tarsini P; Rivoltini L; Maio M; Gallino G; Belli F; Parmiani G
    Eur J Immunol; 1998 Apr; 28(4):1143-54. PubMed ID: 9565353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
    Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
    Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
    Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
    Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.
    Speiser DE; Liénard D; Pittet MJ; Batard P; Rimoldi D; Guillaume P; Cerottini JC; Romero P
    Eur J Immunol; 2002 Mar; 32(3):731-41. PubMed ID: 11870617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
    Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
    Front Immunol; 2018; 9():14. PubMed ID: 29403496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFN-DC Loaded with Autophagosomes containing Virus Antigen is Highly Efficient in Inducing Virus-Specific Human T Cells.
    Fan J; Wu Y; Jiang M; Wang L; Yin D; Zhang Y; Ye W; Yi Y
    Int J Med Sci; 2019; 16(5):741-750. PubMed ID: 31217742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell-derived exosomes in cancer immunotherapy: exploiting nature's antigen delivery pathway.
    Delcayre A; Shu H; Le Pecq JB
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):537-47. PubMed ID: 16001959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide.
    Meijer SL; Dols A; Jensen SM; Hu HM; Miller W; Walker E; Romero P; Fox BA; Urba WJ
    J Immunother; 2007; 30(5):533-43. PubMed ID: 17589294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
    Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
    Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy.
    Li Y; Wang LX; Pang P; Cui Z; Aung S; Haley D; Fox BA; Urba WJ; Hu HM
    Clin Cancer Res; 2011 Nov; 17(22):7047-57. PubMed ID: 22068657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.
    Powell DJ; Dudley ME; Hogan KA; Wunderlich JR; Rosenberg SA
    J Immunol; 2006 Nov; 177(9):6527-39. PubMed ID: 17056585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.